Who makes Milnacipram?

Milnacipram is developed by University of California, San Diego.

What development phase is Milnacipram in?

Milnacipram is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Milnacipram

University of California, San Diego · FDA-approved active Small molecule Quality 0/100

Milnacipram is a marketed drug developed by the University of California, San Diego, with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but it holds a competitive advantage due to its unique mechanism of action. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic name	Milnacipram
Also known as	Savella
Sponsor	University of California, San Diego
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Effect of Milnacipran on Pain in Fibromyalgia (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results